NVP 1503
Alternative Names: NVP-1503Latest Information Update: 13 Sep 2023
At a glance
- Originator Navipharm
- Class Cardiovascular therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cardiovascular disorders
Most Recent Events
- 13 Sep 2023 Discontinued - Preclinical for Cardiovascular disorders in South Korea (unspecified route) (Navipharm pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Cardiovascular-disorders in South Korea
- 03 Aug 2016 Preclinical trials in Cardiovascular disorders in South Korea (unspecified route)